Cannabis-enriched enzymatically treated therapeutic composition
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11839601-B2
Publication Date
2023-12-12
Expiration Date
Abstract
A cannabis-enriched enzymatically treated therapeutic composition. A therapeutic composition is described including water, glucose, glucose reaction product other than sucrose and fructose; a selected amount of a cannabinoid, a cannabinoid reaction product; optionally a terpene and optionally a terpene reaction product. Methods of making and using the compositions are also described.
Core Innovation
The document describes a homogeneous cannabis-enriched therapeutic composition comprising water at up to 30% by weight, at least 30 wt% glucose, at least 5 parts per million of a product of glucose oxidation selected from glucono-lactone, gluconic acid and combinations thereof, and a cannabinoid selected from THC, THCa, CBD, CBDa and combinations thereof at from at least 0.1 parts per million (ppm) to less than 20,000 ppm by weight. The composition further includes at least 1 part per million of a product of cannabinoid oxidation that can be produced from the same said cannabinoid, optionally a terpene, and optionally at least 1 parts per million terpene oxidation product and/or a product of terpene oxidation.
The composition is defined by quantitative weight/weight relationships and by being homogeneous. In particular, a glucose to glucose oxidation product weight/weight ratio is between 10 and 1000, a glucose to cannabinoid weight/weight ratio is greater than 10, and a weight/weight ratio of said cannabinoid to said product of oxidation of said same cannabinoid is between 10 and 1000. The document further frames the cannabinoid oxidation product as being produced from the same cannabinoid selected from THC, THCa, CBD, CBDa and combinations thereof, and treats the terpene and terpene oxidation product as optional components.
The document also describes producing the therapeutic composition and a pharmaceutical product by enzymatically catalyzed conversion using a honey enzyme. In a method, honey and a cannabinoid-containing composition are blended to form cannabinoid-enriched honey, enzyme activity is activated by adding water to provide selected water activity at selected temperature, selected pH and selected duration, and then water is removed to produce enzymatically-catalyzed conversion of at least one of glucose present in honey and the cannabinoid.
Claims Coverage
The document includes two independent claims. Inventive feature coverage centers on a homogeneous therapeutic composition with defined glucose oxidation and cannabinoid oxidation product content and multiple compositional ratios, and a pharmaceutical product produced by honey-based enzyme activation with water addition and removal to produce at least 0.1% by weight conversion of glucose present in honey and/or a cannabinoid under selected water activity, temperature, pH, and duration.
Homogeneous therapeutic composition with defined glucose oxidation and cannabinoid oxidation products
A therapeutic composition comprising water at up to 30% by weight, at least 30 wt% glucose, at least 5 parts per million of a product of glucose oxidation selected from glucono-lactone, gluconic acid and combinations thereof, a cannabinoid selected from THC, THCa, CBD, CBDa and combinations thereof at from at least 0.1 parts per million (ppm) to less than 20,000 ppm by weight, at least 1 part per million of a product of cannabinoid oxidation that can be produced from the same said cannabinoid, optionally a terpene and optionally at least 1 parts per million terpene oxidation product and/or a product of terpene oxidation, wherein the glucose to glucose oxidation product weight/weight ratio is between 10 and 1000, the glucose to cannabinoid weight/weight ratio is greater than 10, the weight/weight ratio of said cannabinoid to said product of oxidation of said same cannabinoid is between 10 and 1000, and the composition is homogeneous.
Pharmaceutical product formed by honey blending and honey-enzyme activation followed by water removal
A pharmaceutical product comprising a therapeutic composition produced according to a method comprising providing honey; providing a cannabinoid-containing composition; blending the honey with the cannabinoid-containing composition to form cannabinoid-enriched honey; activating an enzyme present in the honey by adding water to provide a selected water activity at a selected temperature, selected pH and for a selected duration; and removing water from the cannabinoid-enriched honey, whereby an enzymatically-catalyzed conversion of at least one of glucose present in the honey and cannabinoid is produced, wherein the temperature, pH, water activity and duration are selected to enzymatically-catalyze the conversion of at least 0.1% by weight of the glucose present in the honey, the cannabinoid or both.
Overall claim coverage ties therapeutic benefit to a homogeneous composition that contains defined glucose oxidation products and defined cannabinoid oxidation products at constrained ratios, and to a manufacturing pathway that uses honey enzymes activated by controlled water activity, temperature, pH and duration, followed by water removal to produce at least 0.1% by weight conversion of glucose and/or a cannabinoid.
Stated Advantages
Enhanced therapeutic effect compared with a composition having the same cannabinoid amounts but lacking the specified product of glucose oxidation and the specified cannabinoid reaction product.
Enhanced therapeutic effect for the pharmaceutical product compared with a composition containing the same cannabinoids amounts prepared without applying the enzyme.
Documented Applications
Treating selected medical conditions including post trauma syndrome disorder (PTSD), anxiety, depression, psychosis syndromes, autism, Alzheimer’s disease, Parkinson disease, inflammation, spasticity and muscle tension, pain, epilepsy, stroke, traumatic brain injury, bronchial disorders, cancer, drug abuse, Huntington’s disease, Dystonia, Amyotrophic lateral sclerosis (ALS), Tourette syndrome, Myasthenia gravis, sleep disorders, skin related syndromes, and inflammatory bowel disease.
Interested in licensing this patent?